(three consecutive subcutaneous injections of 100 mg each) at the onset of the cluster period, and then monthly until the end of the cluster period. if a dose of emgality is missed during a cluster period, administer as soon as possible. thereafter, emgality can be scheduled monthly from the date of the last dose until the end of the cluster period. 2.3 important administration instructions emgality is for subcutaneous use only. emgality is intended for patient self-administration. prior to use, provide proper training to patients and/or caregivers on how to prepare and administer emgality using the single-dose prefilled pen or single-dose prefilled syringe, including aseptic technique [see how supplied/storage and handling ( 16.2 ) and instructions for use] : protect emgality from direct sunlight. prior to subcutaneous administration, allow emgality to sit at room temperature for 30 minutes. do not warm by using a heat source such as hot water or a microwave. do not shake the product. inspect emgality visually for particulate matter and discoloration prior to administration, whenever solution and container permit [see dosage forms and strengths ( 3 ) and how supplied/storage and handling ( 16.1 )] . do not use emgality if it is cloudy or there are visible particles. administer emgality in the abdomen, thigh, back of the upper arm, or buttocks subcutaneously. do not inject into areas where the skin is tender, bruised, red, or hard. both the prefilled pen and prefilled syringe are single-dose and deliver the entire contents.

1920 patients were exposed to emgality once monthly for at least 6 months, and 526 patients were exposed for 12 months. in placebo-controlled clinical studies (studies 1, 2, and 3), 705 patients received at least one dose of emgality 120 mg once monthly, and 1451 patients received placebo, during 3 months or 6 months of double-blind treatment [see clinical studies ( 14.1 )] . of the emgality-treated patients, approximately 85% were female, 77% were white, and the mean age was 41 years at study entry. the most common adverse reaction was injection site reactions. in studies 1, 2, and 3, 1.8% of patients discontinued double-blind treatment because of adverse events. table 1 summarizes the adverse reactions that occurred within up to 6 months of treatment in the migraine studies. table 1: adverse reactions occurring in adults with migraine with an incidence of at least 2% for emgality and at least 2% greater than placebo (up to 6 months of treatment) in studies 1, 2, and 3 a injection site reactions include multiple related adverse event terms, such as injection site pain, injection site reaction, injection site erythema, and injection site pruritus. adverse reaction emgality 120 mg monthly (n=705) % placebo monthly (n=1451) % injection site reactions a 18 13 episodic cluster headache emgality was studied for up to 2 months in a placebo-controlled trial in patients with episodic cluster headache (study 4) [see clinical studies ( 14.2 )] . a total of 106 patients were studied (49 on emgality and 57 on placebo). of the emgality-treated patients, approximately 84% were male, 88% were white, and the mean age was 47 years at study entry. two emgality-treated patients discontinued double-blind treatment because of adverse events. overall, the safety profile observed in patients with episodic cluster headache treated with emgality 300 mg monthly is consistent with the safety profile in migraine patients. 6.2 immunogenicity as with all therapeutic proteins, there is potential for immunogenicity. the detection of antibody formation is highly dependent on the sensitivity and specificity of the assay. additionally, the observed incidence of antibody (including neutralizing antibody) positivity in an assay may be influenced by several factors including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. for these reasons, comparison of the incidence of antibodies to galcanezumab-gnlm in the studies described below with the incidence of antibodies in other studies or to other products may be misleading. the immunogenicity of emgality has been evaluated using an in vitro immunoassay for the detection of binding anti-galcanezumab-gnlm antibodies. for patients whose sera tested positive in the screening immunoassay, an in vitro ligand-binding immunoassay was performed to detect neutralizing antibodies. in controlled studies with emgality up to 6 months (study 1, study 2, and study 3), the incidence of anti-galcanezumab-gnlm antibody development was 4.8% (33/688) in patients receiving emgality once monthly (32 out of 33 of whom had in vitro neutralizing activity). with 12 months of treatment in an open-label study, up to 12.5% (16/128) of emgality-treated patients developed anti-galcanezumab-gnlm antibodies, most of whom tested positive for neutralizing antibodies. although anti-galcanezumab-gnlm antibody development was not found to affect the pharmacokinetics, safety or efficacy of emgality in these patients, the available data are too limited to make definitive conclusions. 6.3 postmarketing experience the following adverse reactions have been identified during post-approval use of emgality. because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to emgality exposure. immune system disorders — anaphylaxis, angioedema [see contraindications ( 4 ) and warnings and precautions ( 5.1 )] . skin and subcutaneous tissue disorders — rash.

rth defects (2.2% - 2.9%) and miscarriage (17%) among deliveries to women with migraine are similar to rates reported in women without migraine. clinical considerations disease-associated maternal and/or embryo/fetal risk published data have suggested that women with migraine may be at increased risk of preeclampsia during pregnancy. data animal data when galcanezumab-gnlm was administered to female rats by subcutaneous injection in two studies (0, 30, or 100 mg/kg; 0 or 250 mg/kg) prior to and during mating and continuing throughout organogenesis, no adverse effects on embryofetal development were observed. the highest dose tested (250 mg/kg) was associated with a plasma exposure (c ave, ss ) 38 or 18 times that in humans at the recommended human dose (rhd) for migraine (120 mg) or episodic cluster headache (300 mg), respectively. administration of galcanezumab-gnlm (0, 30, or 100 mg/kg) by subcutaneous injection to pregnant rabbits throughout the period of organogenesis produced no adverse effects on embryofetal development. the higher dose tested was associated with a plasma c ave, ss 64 or 29 times that in humans at 120 mg or 300 mg, respectively. administration of galcanezumab-gnlm (0, 30, or 250 mg/kg) by subcutaneous injection to rats throughout pregnancy and lactation produced no adverse effects on pre- and postnatal development. the higher dose tested was associated with a plasma c ave, ss 34 or 16 times that in humans at 120 mg or 300 mg, respectively. 8.2 lactation risk summary there are no data on the presence of galcanezumab-gnlm in human milk, the effects on the breastfed infant, or the effects on milk production. the developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for emgality and any potential adverse effects on the breastfed infant from emgality or from the underlying maternal condition. 8.4 pediatric use safety and effectiveness in pediatric patients have not been established. 8.5 geriatric use clinical studies of emgality did not include sufficient numbers of patients aged 65 and over to determine whether they respond differently from younger patients.

miscarriage (17%) among deliveries to women with migraine are similar to rates reported in women without migraine. clinical considerations disease-associated maternal and/or embryo/fetal risk published data have suggested that women with migraine may be at increased risk of preeclampsia during pregnancy. data animal data when galcanezumab-gnlm was administered to female rats by subcutaneous injection in two studies (0, 30, or 100 mg/kg; 0 or 250 mg/kg) prior to and during mating and continuing throughout organogenesis, no adverse effects on embryofetal development were observed. the highest dose tested (250 mg/kg) was associated with a plasma exposure (c ave, ss ) 38 or 18 times that in humans at the recommended human dose (rhd) for migraine (120 mg) or episodic cluster headache (300 mg), respectively. administration of galcanezumab-gnlm (0, 30, or 100 mg/kg) by subcutaneous injection to pregnant rabbits throughout the period of organogenesis produced no adverse effects on embryofetal development. the higher dose tested was associated with a plasma c ave, ss 64 or 29 times that in humans at 120 mg or 300 mg, respectively. administration of galcanezumab-gnlm (0, 30, or 250 mg/kg) by subcutaneous injection to rats throughout pregnancy and lactation produced no adverse effects on pre- and postnatal development. the higher dose tested was associated with a plasma c ave, ss 34 or 16 times that in humans at 120 mg or 300 mg, respectively.

ion was about 5 days. injection site location did not significantly influence the absorption of galcanezumab-gnlm. distribution the apparent volume of distribution (v/f) of galcanezumab-gnlm was 7.3 l (34% inter individual variability [iiv]). metabolism and elimination galcanezumab-gnlm is expected to be degraded into small peptides and amino acids via catabolic pathways in the same manner as endogenous igg. the apparent clearance (cl/f) of galcanezumab-gnlm was 0.008 l/h and the elimination half-life of galcanezumab was approximately 27 days. specific populations age, sex, weight, race, ethnicity the pharmacokinetics of galcanezumab-gnlm were not affected by age, sex, race, subtypes of migraine spectrum (episodic or chronic migraine), or headache diagnosis (migraine vs. episodic cluster headache) based on a population pharmacokinetics analysis. body weight has no clinically relevant effect on the pharmacokinetics of galcanezumab-gnlm. patients with renal or hepatic impairment renal and hepatic impairment are not expected to affect the pharmacokinetics of galcanezumab-gnlm. population pharmacokinetic analysis of integrated data from the galcanezumab-gnlm clinical studies revealed that creatinine clearance did not affect the pharmacokinetics of galcanezumab-gnlm in patients with mild or moderate renal impairment. patients with severe renal impairment (creatinine clearance <30 ml/min) have not been studied. based on a population pk analysis, bilirubin concentration did not significantly influence the cl/f of galcanezumab-gnlm. no dedicated clinical studies were conducted to evaluate the effect of hepatic impairment or renal impairment on the pharmacokinetics of galcanezumab-gnlm. drug interaction studies p450 enzymes galcanezumab-gnlm is not metabolized by cytochrome p450 enzymes; therefore, interactions with concomitant medications that are substrates, inducers, or inhibitors of cytochrome p450 enzymes are unlikely.

degraded into small peptides and amino acids via catabolic pathways in the same manner as endogenous igg. the apparent clearance (cl/f) of galcanezumab-gnlm was 0.008 l/h and the elimination half-life of galcanezumab was approximately 27 days. specific populations age, sex, weight, race, ethnicity the pharmacokinetics of galcanezumab-gnlm were not affected by age, sex, race, subtypes of migraine spectrum (episodic or chronic migraine), or headache diagnosis (migraine vs. episodic cluster headache) based on a population pharmacokinetics analysis. body weight has no clinically relevant effect on the pharmacokinetics of galcanezumab-gnlm. patients with renal or hepatic impairment renal and hepatic impairment are not expected to affect the pharmacokinetics of galcanezumab-gnlm. population pharmacokinetic analysis of integrated data from the galcanezumab-gnlm clinical studies revealed that creatinine clearance did not affect the pharmacokinetics of galcanezumab-gnlm in patients with mild or moderate renal impairment. patients with severe renal impairment (creatinine clearance <30 ml/min) have not been studied. based on a population pk analysis, bilirubin concentration did not significantly influence the cl/f of galcanezumab-gnlm. no dedicated clinical studies were conducted to evaluate the effect of hepatic impairment or renal impairment on the pharmacokinetics of galcanezumab-gnlm. drug interaction studies p450 enzymes galcanezumab-gnlm is not metabolized by cytochrome p450 enzymes; therefore, interactions with concomitant medications that are substrates, inducers, or inhibitors of cytochrome p450 enzymes are unlikely.

times that in humans at 120 mg or 300 mg, respectively.

0 mg or 300 mg, respectively.

cation overuse headache, patients with ecg abnormalities compatible with an acute cardiovascular event and patients with a history of stroke, myocardial infarction, unstable angina, percutaneous coronary intervention, coronary artery bypass grafting, deep vein thrombosis, or pulmonary embolism within 6 months of screening. the primary efficacy endpoint for studies 1 and 2 was the mean change from baseline in the number of monthly migraine headache days over the 6-month treatment period. key secondary endpoints included response rates (the mean percentages of patients reaching at least 50%, 75%, and 100% reduction from baseline in the number of monthly migraine headache days over the 6-month treatment period), the mean change from baseline in the number of monthly migraine headache days with use of any acute headache medication during the 6-month treatment period, and the impact of migraine on daily activities, as assessed by the mean change from baseline in the average migraine-specific quality of life questionnaire version 2.1 (msq v2.1) role function-restrictive domain score during the last 3 months of treatment (months 4 to 6). scores are scaled from 0 to 100, with higher scores indicating less impact of migraine on daily activities. in study 1, a total of 858 patients (718 females, 140 males) ranging in age from 18 to 65 years, were randomized. a total of 703 patients completed the 6-month double-blind phase. in study 2, a total of 915 patients (781 female, 134 male) ranging in age from 18 to 65 years, were randomized. a total of 785 patients completed the 6-month double-blind phase. in study 1 and study 2, the mean migraine frequency at baseline was approximately 9 migraine days per month, and was similar across treatment groups. emgality 120 mg demonstrated statistically significant improvements for efficacy endpoints compared to placebo over the 6-month period, as summarized in table 2 . emgality treatment with the 240 mg once-monthly dose showed no additional benefit over the emgality 120 mg once-monthly dose. table 2: efficacy endpoints in studies 1 and 2 a p<0.001 b n = 189 for emgality 120 mg and n = 377 for placebo in study 1; n = 213 for emgality 120 mg and n = 396 for placebo in study 2. study 1 study 2 emgality 120 mg n = 210 placebo n = 425 emgality 120 mg n = 226 placebo n = 450 monthly migraine headache days (over months 1 to 6) baseline migraine headache days 9.2 9.1 9.1 9.2 mean change from baseline -4.7 -2.8 -4.3 -2.3 difference from placebo a -1.9 -2.0 ?50% migraine headache days responders (over months 1 to 6) % responders a 62% 39% 59% 36% ?75% migraine headache days responders (over months 1 to 6) % responders a 39% 19% 34% 18% 100% migraine headache days responders (over months 1 to 6) % responders a 16% 6% 12% 6% monthly migraine headache days that acute medication was taken (over months 1 to 6) mean change from baseline (days) a -4.0 -2.2 -3.7 -1.9 msq role function-restrictive domain score (over months 4 to 6) baseline 51.4 52.9 52.5 51.4 mean change from baseline b 32.4 24.7 28.5 19.7 difference from placebo a 7.7 8.8 figure 1: change from baseline in monthly migraine headache days in study 1 a a least-square means and 95% confidence intervals are presented. figure 2: change from baseline in monthly migraine headache days in study 2 a a least-square means and 95% confidence intervals are presented. figure 3 shows the distribution of change from baseline in the mean number of monthly migraine headache days in bins of 2 days, by treatment group, in study 1. a treatment benefit over placebo for emgality is seen across a range of changes from baseline in monthly migraine headache days. figure 3: distribution of change from baseline in mean monthly migraine headache days over months 1 to 6 by treatment group in study 1 figure 4 shows the distribution of change from baseline in the mean number of monthly migraine headache days in bins of 2 days, by treatment group, in study 2. a treatment benefit over placebo for emgality is seen across a range of changes from baseline in monthly migraine headache days. figure 4: distribution of change from baseline in mean monthly migraine headache days over months 1 to 6 by treatment group in study 2 figure 1 figure 2 figure 3 figure 4 chronic migraine study 3 (nct02614261) included adults with a history of chronic migraine (?15 headache days per month with ?8 migraine days per month). all patients were randomized in a 1:1:2 ratio to receive once-monthly subcutaneous injections of emgality 120 mg, emgality 240 mg, or placebo over a 3-month treatment period. all patients in the 120 mg emgality group received an initial 240 mg loading dose. patients were allowed to use acute headache treatments including migraine-specific medications (i.e., triptans, ergotamine derivatives), nsaids, and acetaminophen. a subset of patients (15%) was allowed to use one concomitant migraine preventive medication. patients with medication overuse headache were allowed to enroll. the study excluded patients with ecg abnormalities compatible with an acute cardiovascular event, and patients with a history of stroke, myocardial infarction, unstable angina, percutaneous coronary intervention, coronary artery bypass grafting, deep vein thrombosis, or pulmonary embolism within 6 months of screening. the primary endpoint was the mean change from baseline in the number of monthly migraine headache days over the 3-month treatment period. the secondary endpoints were response rates (the mean percentages of patients reaching at least 50%, 75% and 100% reduction from baseline in the number of monthly migraine headache days over the 3-month treatment period), the mean change from baseline in the number of monthly migraine headache days with use of any acute headache medication during the 3-month treatment period, and the impact of migraine on daily activities as assessed by the mean change from baseline in the msq v2.1 role function-restrictive domain score at month 3. scores are scaled from 0 to 100, with higher scores indicating less impact of migraine on daily activities. in study 3, a total of 1113 patients (946 female, 167 male) ranging in age from 18 to 65 years, were randomized. a total of 1037 patients completed the 3-month double-blind phase. the mean number of monthly migraine headache days at baseline was approximately 19. emgality 120 mg demonstrated statistically significant improvement for the mean change from baseline in the number of monthly migraine headache days over the 3-month treatment period, and in the mean percentage of patients reaching at least 50% reduction from baseline in the number of monthly migraine headache days over the 3-month treatment period, as summarized in table 3 . emgality treatment with the 240 mg once-monthly dose showed no additional benefit over the emgality 120 mg once-monthly dose. table 3: efficacy endpoints in study 3 a p<0.001 emgality 120 mg n = 273 placebo n =538 monthly migraine headache days (over months 1 to 3) baseline migraine headache days 19.4 19.6 mean change from baseline -4.8 -2.7 difference from placebo a -2.1 ?50% migraine headache days responders (over months 1 to 3) % responders a 28% 15% study 3 utilized a sequential testing procedure to control the type-i error rate for the multiple secondary endpoints. once a secondary endpoint failed to reach the required level for statistical significance, formal hypothesis testing was terminated for subsequent endpoints, and p-values were considered nominal only. in study 3, emgality 120 mg was not significantly better than placebo for the proportion of patients with ?75% or 100% reduction in migraine headache days. patients treated with emgality 120 mg showed a nominally greater reduction in the number of monthly migraine headache days that acute medication was taken (-4.7 for emgality 120 mg vs. -2.2 for placebo; nominal p-value <0.001), and the mean change from baseline in the msq role function-restrictive domain score at month 3 was nominally greater in patients treated with emgality 120 mg than in patients on placebo (21.8 for emgality 120 mg vs. 16.8 for placebo; nominal p-value <0.001). figure 5: change from baseline in monthly migraine headache days in study 3 a a least-square means and 95% confidence intervals are presented. figure 6 shows the distribution of change from baseline in the mean number of monthly migraine headache days for the 3-month study period in bins of 3 days by treatment group. a treatment benefit over placebo for emgality is seen across a range of changes from baseline in monthly migraine headache days. figure 6: distribution of change from baseline in mean monthly migraine headache days over months 1 to 3 by treatment group in study 3 figure 6 figure 6 14.2 episodic cluster headache the efficacy of emgality was evaluated for the treatment of episodic cluster headache in a randomized, 8-week, double-blind, placebo-controlled study (study 4). study 4 (nct02397473) included adults who met the international classification of headache disorders 3 rd edition (beta version) diagnostic criteria for episodic cluster headache and had a maximum of 8 attacks per day, a minimum of one attack every other day, and at least 4 attacks during the prospective 7-day baseline period. all patients were randomized in a 1:1 ratio to receive once-monthly subcutaneous injections of emgality 300 mg or placebo. patients were allowed to use certain specified acute/abortive cluster headache treatments, including triptans, oxygen, acetaminophen, and nsaids during the study. the study excluded patients on other treatments intended to reduce the frequency of cluster headache attacks; patients with medication overuse headache; patients with ecg abnormalities compatible with an acute cardiovascular event or conduction delay; and patients with a history of myocardial infarction, unstable angina, percutaneous coronary intervention, coronary artery bypass grafting, deep vein thrombosis, or pulmonary embolism within 6 months of screening. in addition, patients with any history of stroke, intracranial or carotid aneurysm, intracranial hemorrhage, or vasospastic angina; clinical evidence of peripheral vascular disease; or diagnosis of raynaud’s disease were excluded. the primary efficacy endpoint for study 4 was the mean change from baseline in weekly cluster headache attack frequency across weeks 1 to 3. a secondary endpoint was the percentage of patients who achieved a response (defined as a reduction from baseline of 50% or greater in the weekly cluster headache attack frequency) at week 3. in study 4, a total of 106 patients (88 males, 18 females) ranging in age from 19 to 65 years were randomized and treated. a total of 90 patients completed the 8-week double-blind phase. in the prospective baseline phase, the mean number of weekly cluster headache attacks was 17.5, and was similar across treatment groups. emgality 300 mg demonstrated statistically significant improvements for efficacy endpoints compared to placebo, as summarized in table 4 . table 4: efficacy endpoints in study 4 emgality 300 mg n = 49 placebo n = 57 mean reduction in weekly cluster headache attack frequency (over weeks 1 to 3) prospective baseline cluster headache attack frequency 17.8 17.3 mean change from baseline -8.7 -5.2 difference from placebo -3.5 p-value 0.036 ?50% weekly cluster headache attack frequency responders (at week 3) % responders 71.4% 52.6% difference from placebo 18.8% p-value 0.046 figure 7: mean change in weekly cluster headache attack frequency over weeks 1 to 3 in study 4 a a abbreviations: bl = baseline; ls = least square; se = standard error. figure 8 shows the distribution of the average percent change from baseline in weekly cluster headache attack frequency across weeks 1 to 3 in bins of 25%, by treatment group, in study 4. figure 8: distribution of the average percent change from baseline in weekly cluster headache attack frequency over weeks 1 to 3 in study 4 a a n = number of intent to treat patients with non-missing average percentage change from baseline in weekly cluster headache attack frequency over weeks 1 to 3. figure 7 figure 8

mgality must be discarded. discard the emgality single-dose prefilled pen or syringe after use in a puncture-resistant container.

). literature revised: 03/2021 eli lilly and company, indianapolis, in 46285, usa us license number 1891 copyright © 2018, 2021, eli lilly and company. all rights reserved. emg-0006-uspi-20210311

1-833-464-4724 or by visiting www.migrainepregnancyregistry.com. or you may talk to your healthcare provider about how you can take part in this registry. are breastfeeding or plan to breastfeed. it is not known if emgality passes into your breast milk. talk to your healthcare provider about the best way to feed your baby while using emgality. tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. know the medicines you take. keep a list of your medicines with you to show your healthcare provider and pharmacist when you get a new medicine. how should i use emgality? see the instructions for use that come with emgality prefilled pen or prefilled syringe about how to use emgality the right way. use emgality exactly as your healthcare provider tells you to. emgality is given by injection under the skin (subcutaneous injection). inject emgality in your stomach area (abdomen), thigh, back of the upper arm, or buttocks. your healthcare provider should show you or a caregiver how to prepare and inject emgality the right way before you start to use it. emgality comes in 2 different types of devices: a single-dose (1 time) prefilled pen a single-dose (1 time) prefilled syringe your healthcare provider will prescribe the type that is best for you. if you have questions about injecting the medicine, talk to your pharmacist or healthcare provider. if you are using the emgality 120 mg prefilled pen or prefilled syringe for migraine: inject emgality 1 time each month. for the first dose (loading dose), you will get 2 separate injections one time, right after each other. you will need 2 prefilled pens or 2 prefilled syringes for your first dose (1-time loading dose). for your regular monthly dose, you will get 1 injection. you will need 1 prefilled pen or 1 prefilled syringe for your regular monthly dose. if you miss a dose of emgality, inject the missed dose as soon as possible. then inject emgality 1 month from the date of your last dose to get back on a monthly dosing schedule. if you have questions about your schedule, ask your healthcare provider. if you are using the emgality 100 mg prefilled syringe for episodic cluster headache: you will get 3 separate injections, right after each other, using 3 prefilled syringes for each of your doses. use emgality at the start of a cluster period and then every month until the end of the cluster period. if you miss a dose of emgality, inject the missed dose as soon as possible. then, if the cluster headache period has not yet ended, inject emgality 1 month after your last dose to get back on a monthly dosing schedule. if you have questions about when you should use emgality, ask your healthcare provider. what are the possible side effects of emgality? emgality may cause serious side effects, including: allergic reactions. allergic reactions, including itching, rash, hives, and trouble breathing, can happen after receiving emgality. this can happen days after using emgality. call your healthcare provider or get emergency medical help right away if you have any of the following symptoms, which may be part of an allergic reaction: swelling of the face, mouth, tongue, or throat trouble breathing the most common side effects of emgality include: injection site reactions tell your healthcare provider if you have any side effect that bothers you or that does not go away. these are not all of the possible side effects of emgality. for more information, ask your healthcare provider or pharmacist. call your healthcare provider for medical advice about side effects. you may report side effects to fda at 1-800-fda-1088. how should i store emgality? store emgality in the refrigerator between 36°f to 46°f (2°c to 8°c). emgality may be stored out of the refrigerator in the original carton at temperatures up to 86°f (30°c) for up to 7 days. after storing out of the refrigerator, do not place emgality back in the refrigerator. do not freeze emgality. keep emgality in the carton it comes in to protect it from light until time of use. do not shake emgality. throw away emgality if any of the above conditions are not followed. keep emgality and all medicines out of the reach of children. general information about the safe and effective use of emgality. medicines are sometimes prescribed for purposes other than those listed in the patient information. do not use emgality for a condition for which it was not prescribed. do not give emgality to other people, even if they have the same symptoms you have. it may harm them. you can ask your pharmacist or healthcare provider for information about emgality that is written for health professionals. what are the ingredients in emgality? active ingredient: galcanezumab-gnlm inactive ingredients: l-histidine, l-histidine hydrochloride monohydrate, polysorbate 80, sodium chloride, and water for injection, usp. emgality prefilled pen and prefilled syringes are not made with natural rubber latex. emgality ® is a registered trademark of eli lilly and company. eli lilly and company indianapolis, in 46285, usa us license number 1891 copyright © 2018, 2021, eli lilly and company. all rights reserved. emg-0005-ppi-20210311 for more information, call 1-833-emgality (1-833-364-2548) or go to www.emgality.com.